Skip to main content
SpringerLink
Log in

Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma often with extranodal involvement at diagnosis, and yet how this feature correlates with survival awaits elucidation. To address this issue, a correlative analysis between clinical features of 127 MCL patients and their overall survival (OS) was conducted. In this cohort, the median age at MCL diagnosis was 62 years and 81% were males. Eighty-four percent of patients were Ann Arbor stage 4, and 15% were blastoid variants. In patients with gastrointestinal MCL, approximately 40% had gastric involvement. In treatment, CHOP-based induction chemotherapy was given to 61.1% of patients. One-third of patients undertook autologous stem cell transplant (SCT), and 4.7% had allogeneic SCT. The median OS was 82 months and well-stratified in MIPI risk groups. In the multivariate analysis for OS, blastoid variants and gastric involvement were both independent risk factors whereas auto-SCT had a protective effect. Overall, this study corroborated with the current understandings and international therapeutic standards for MCL. Auto-SCT associated with a better OS while allo-SCT remained an option for blastoid variants and those who failed Auto-SCT. Interestingly, patients with gastric involvement tended to have worse survival, a finding that spawns more studies to investigate the mechanism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–62.

    Article  CAS  PubMed  Google Scholar 

  2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–78.

    Article  CAS  PubMed  Google Scholar 

  4. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97:586–91.

    Article  PubMed  Google Scholar 

  5. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  CAS  PubMed  Google Scholar 

  6. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013;121:48–53.

    Article  CAS  PubMed  Google Scholar 

  7. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the Rituximab Era. J Clin Oncol. 2019;37:471–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25:1053–8.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9:50.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016;172:208–18.

    Article  CAS  PubMed  Google Scholar 

  11. Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–31.

    Article  CAS  PubMed  Google Scholar 

  13. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018;182:404–11.

    Article  CAS  PubMed  Google Scholar 

  14. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179:430–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184:1006–100.

    CAS  PubMed  Google Scholar 

  16. Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2019;184:999–1005.

    Article  CAS  PubMed  Google Scholar 

  17. Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009;2:103–11.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824–33.

    Article  PubMed  Google Scholar 

  19. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.

    Article  CAS  PubMed  Google Scholar 

  20. Saito M, Miyazaki M, Tanino M, Tanaka S, Miyashita K, Izumiyama K, et al. (1)(8)F-FDG PET/CT imaging for a gastrointestinal mantle cell lymphoma with multiple lymphomatous polyposis. World J Gastroenterol. 2014;20:5141–6.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bailly C, Carlier T, Touzeau C, Arlicot N, Kraeber-Bodere F, Le Gouill S, et al. Interest of FDG-PET in the management of mantle cell lymphoma. Front Med (Lausanne). 2019;6:70.

    Article  Google Scholar 

  22. Bhatia K, Sahdev A, Reznek RH. Lymphoma of the spleen. Semin Ultrasound CT MR. 2007;28:12–20.

    Article  PubMed  Google Scholar 

  23. Rabushka LS, Kawashima A, Fishman EK. Imaging of the spleen: CT with supplemental MR examination. Radiographics. 1994;14:307–32.

    Article  CAS  PubMed  Google Scholar 

  24. Robertson F, Leander P, Ekberg O. Radiology of the spleen. Eur Radiol. 2001;11:80–95.

    Article  CAS  PubMed  Google Scholar 

  25. Saboo SS, Krajewski KM, O'Regan KN, Giardino A, Brown JR, Ramaiya N, et al. Spleen in haematological malignancies: spectrum of imaging findings. Br J Radiol. 2012;85:81–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Leite NP, Kased N, Hanna RF, Brown MA, Pereira JM, Cunha R, et al. Cross-sectional imaging of extranodal involvement in abdominopelvic lymphoproliferative malignancies. Radiographics. 2007;27:1613–34.

    Article  PubMed  Google Scholar 

  27. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–6.

    Article  CAS  PubMed  Google Scholar 

  28. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984–92.

    Article  CAS  PubMed  Google Scholar 

  29. Takahashi Y, Mori J, Tanimoto T. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:1765 (author reply-6).

    Article  CAS  PubMed  Google Scholar 

  30. Lipsky A, Martin P. Bendamustine-rituximab in mantle cell lymphoma. Lancet Haematol. 2017;4:e2–e3.

    Article  PubMed  Google Scholar 

  31. Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015;94:2025–32.

    Article  CAS  PubMed  Google Scholar 

  32. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172:80–8.

    Article  CAS  PubMed  Google Scholar 

  34. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156:346–53.

    Article  CAS  PubMed  Google Scholar 

  35. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013–23.

    Article  CAS  PubMed  Google Scholar 

  36. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–53.

    Article  CAS  PubMed  Google Scholar 

  37. Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19:1449–588.

    Article  CAS  PubMed  Google Scholar 

  38. Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4:e15–e23.

    Article  PubMed  Google Scholar 

  39. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–9.

    Article  CAS  PubMed  Google Scholar 

  40. Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH, et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(−2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer. 2000;82:278–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16:587–93.

    Article  CAS  PubMed  Google Scholar 

  42. Anderson CC, Goldstone AH, Souhami RL, Linch DC, Harper PG, McLennan KA, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol. 1986;16:170–5.

    Article  CAS  PubMed  Google Scholar 

  43. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:588–95.

    Article  CAS  PubMed  Google Scholar 

  44. Salar A, Juanpere N, Bellosillo B, Domingo-Domenech E, Espinet B, Seoane A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 2006;30:1274–80.

    Article  PubMed  Google Scholar 

  45. Lamm W, Dolak W, Kiesewetter B, Simonitsch-Klupp I, Puhr H, Raderer M. Gastrointestinal involvement in patients with mantle cell lymphoma: a single center experience of eighty-five patients. Dig Dis. 2019;37:194–200.

    Article  PubMed  Google Scholar 

  46. Augoff K, Hryniewicz-Jankowska A, Tabola R. Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett. 2015;358:1–7.

    Article  CAS  PubMed  Google Scholar 

  47. Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989;59:276–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Endrizzi L, Fiorentino MV, Salvagno L, Segati R, Pappagallo GL, Fosser V. Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1982;18:945–9.

    Article  CAS  PubMed  Google Scholar 

  49. Steensma DP, Witzig TE. Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign. Br J Haematol. 1999;107:463–4.

    Article  CAS  PubMed  Google Scholar 

  50. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, et al. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020;4:1038–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Zheng QF, Li JY, Qin L, Wei HM, Cai LY, Nong B. Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: a case report. Medicine (Baltimore). 2018;97:e9799.

    Article  Google Scholar 

  52. Smith LB, Owens SR. Gastrointestinal lymphomas: entities and mimics. Arch Pathol Lab Med. 2012;136:865–70.

    Article  PubMed  Google Scholar 

  53. Petranovic D, Pilcic G, Peitl M, Cubranic A, Valkovic T, Nacinovic AD, et al. Primary gastric mantle cell lymphoma. Hematol Rep. 2012;4:e1.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Murali S, Winton E, Waller EK, Heffner LT, Lonial S, Flowers C, et al. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone Marrow Transplant. 2008;42:529–34.

    Article  CAS  PubMed  Google Scholar 

  55. Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166–71.

    Article  CAS  PubMed  Google Scholar 

  56. Yoon DH, Cao J, Chen TY, Izutsu K, Kim SJ, Kwong YL, et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol. 2020;13:21.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273–81.

    Article  PubMed  Google Scholar 

  58. Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant. 2016;51:1184–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the service provided by Department of Laboratory Medicine, Department of Pathology, and Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital. We would also like to acknowledge the cases contributed by Dr. Ruei-Je Chen, National Taiwan University Hospital Hsin-Chu Branch, and Dr. Yu-Chin Hung, National Taiwan University Hospital Yunlin Branch.

Author information

Authors and Affiliations

  1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

    Yu-Hung Wang & Yi-Tsung Yang

  2. Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan S. Rd., Taipei City, 10002, Taiwan

    Yu-Hung Wang, Bor-Sheng Ko, Ming Yao, Jih-Luh Tang & Tai-Chung Huang

  3. Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan

    Shan-Chi Yu

  4. Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan

    Bor-Sheng Ko & Jih-Luh Tang

  5. Division of Hematology-Oncology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan

    Yi-Tsung Yang

Authors
  1. Yu-Hung Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shan-Chi Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bor-Sheng Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi-Tsung Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jih-Luh Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tai-Chung Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YHW was responsible for data collection and management, statistical analysis and interpretation, literature research, and manuscript writing; SCY was responsible for pathologic review and data collection; YTY, BSK, and MY were responsible for data collection and management; and JLT and TCH planned, designed, and coordinated the study over the entire period and wrote the manuscript.

Corresponding author

Correspondence to Tai-Chung Huang.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 545 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, YH., Yu, SC., Ko, BS. et al. Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. Int J Hematol 112, 385–394 (2020). https://doi.org/10.1007/s12185-020-02903-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02903-z

Keywords

Search

Navigation